Gurus Trade in British-Based Pharmaceutical Stock in Fourth Quarter

Mar 04, 2015

With health care being such a prominent topic, it shouldn’t come as a surprise that some gurus have been trading in companies whose products promote better health.

One such company is England-based GlaxoSmithKline (GSK.UK, Financial), a multinational pharmaceutical, biologics, vaccines and consumer health care company. It specializes in drugs for major health issues such as asthma, cancer, infections, diabetes, digestive and mental health conditions. Nearly a year ago, GlaxoSmithKline was listed as the sixth-largest pharmaceutical company in the world based on its 2013 revenue.

Two gurus added it to their portfolios in the fourth quarter of 2014, and one guru sold a portion of his stake in the company. Two other gurus also have GSK in their portfolios, but neither guru bought nor sold it in the fourth quarter.

Causeway International Value (Trades, Portfolio) bought 5,269,224 shares of GlaxoSmithKline for an average price of £14.13 a share (approximately $21.72 in U.S. dollars). The purchase had a 1.8% impact on Causeway’s portfolio.

Bestinfond (Trades, Portfolio) also added GlaxoSmithKline to its portfolio in the fourth quarter, buying 668,556 shares for the same average price of £14.13 a share. The transaction had a 1% impact on Bestinfond (Trades, Portfolio)’s portfolio.

David Herro sold a portion of his stake in the company in the fourth quarter. Herro sold 2,763,000 shares for that same average price; the sale had a -0.22% impact on his portfolio and left Herro with 19,789,000 shares of GSK in his possession. It is the 15th-largest stake in Herro’s portfolio.

While he didn’t trade in GSK in the fourth quarter, guru Brian Rogers (Trades, Portfolio), portfolio manager of T. Rowe Price Equity Income Fund (PRFDX), has 6,250,000 shares of GlaxoSmithKline in his portfolio.

Tweedy Browne (Trades, Portfolio) Global Value didn’t trade in GSK in the fourth quarter, either, but it has 3,671,198 shares in the company in its portfolio.

To view international stock purchases, visit the Guru's International Picks page. Not a premium member of GuruFocus? Try it free for 7 days.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.